These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 7424621)

  • 61. A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis.
    Perez-Ruiz F; Herrero-Beites AM; Carmona L
    Arthritis Rheum; 2011 Dec; 63(12):4002-6. PubMed ID: 21898351
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Diagnostic value of renal urate excretion].
    Häntzschel U; Költzsch V
    Z Gesamte Inn Med; 1978 Mar; 33(6):180-4. PubMed ID: 645153
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Dynamics of uric acid metabolism in hyperuricemia].
    Nakamura T; Takagi K; Ueda T
    Nihon Rinsho; 1996 Dec; 54(12):3230-6. PubMed ID: 8976097
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Hyperuricemia and gout following pediatric renal transplantation.
    Spartà G; Kemper MJ; Neuhaus TJ
    Pediatr Nephrol; 2006 Dec; 21(12):1884-8. PubMed ID: 16947031
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Study on the diagnosis of gout with xanthine and hypoxanthine.
    Wang Y; Deng M; Deng B; Ye L; Fei X; Huang Z
    J Clin Lab Anal; 2019 Jun; 33(5):e22868. PubMed ID: 30803031
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Hyperuricemia and gout in thyroid endocrine disorders.
    Giordano N; Santacroce C; Mattii G; Geraci S; Amendola A; Gennari C
    Clin Exp Rheumatol; 2001; 19(6):661-5. PubMed ID: 11791637
    [TBL] [Abstract][Full Text] [Related]  

  • 67. ABCG2/BCRP dysfunction as a major cause of gout.
    Matsuo H; Takada T; Ichida K; Nakamura T; Nakayama A; Suzuki H; Hosoya T; Shinomiya N
    Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1117-28. PubMed ID: 22132966
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.
    Miner JN; Tan PK; Hyndman D; Liu S; Iverson C; Nanavati P; Hagerty DT; Manhard K; Shen Z; Girardet JL; Yeh LT; Terkeltaub R; Quart B
    Arthritis Res Ther; 2016 Oct; 18(1):214. PubMed ID: 27716403
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Heredity in gout and hyperuricemia.
    HAUGE M; HARVALD B
    Acta Med Scand; 1955 Nov; 152(4):247-57. PubMed ID: 13292148
    [No Abstract]   [Full Text] [Related]  

  • 70. [Considerations on the pathogenesis of hyperuricemia in the gout patient].
    VILLA L; BALLABIO CB
    Viata Med; 1961 May; 8():551-4. PubMed ID: 13781370
    [No Abstract]   [Full Text] [Related]  

  • 71. Plasma and Urinary Metabolomic Analysis of Gout and Asymptomatic Hyperuricemia and Profiling of Potential Biomarkers: A Pilot Study.
    Ohashi Y; Ooyama H; Makinoshima H; Takada T; Matsuo H; Ichida K
    Biomedicines; 2024 Jan; 12(2):. PubMed ID: 38397902
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Differences in MSU-induced superoxide responses by neutrophils from gout subjects compared to healthy controls and a role for environmental inflammatory cytokines and hyperuricemia in neutrophil function and survival.
    Martin WJ; Grainger R; Harrison A; Harper JL
    J Rheumatol; 2010 Jun; 37(6):1228-35. PubMed ID: 20395644
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study.
    Campion EW; Glynn RJ; DeLabry LO
    Am J Med; 1987 Mar; 82(3):421-6. PubMed ID: 3826098
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Genetic disorders resulting in hyper- or hypouricemia.
    Sebesta I
    Adv Chronic Kidney Dis; 2012 Nov; 19(6):398-403. PubMed ID: 23089275
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Review of the ophthalmic manifestations of gout and uric acid crystal deposition.
    Ao J; Goldblatt F; Casson RJ
    Clin Exp Ophthalmol; 2017 Jan; 45(1):73-80. PubMed ID: 27010973
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Trends in hyperuricemia and gout prevalence: Nutrition and Health Survey in Taiwan from 1993-1996 to 2005-2008.
    Chuang SY; Lee SC; Hsieh YT; Pan WH
    Asia Pac J Clin Nutr; 2011; 20(2):301-8. PubMed ID: 21669599
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Therapy of hyperuricemia and gout].
    Pöllmann G; Kullich W; Klein G
    Wien Med Wochenschr; 1997; 147(16):382-7. PubMed ID: 9446417
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China.
    Miao Z; Li C; Chen Y; Zhao S; Wang Y; Wang Z; Chen X; Xu F; Wang F; Sun R; Hu J; Song W; Yan S; Wang CY
    J Rheumatol; 2008 Sep; 35(9):1859-64. PubMed ID: 18634142
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Hyperglutamatemia in primary gout.
    Gutman AB; Yu TF
    Am J Med; 1973 Jun; 54(6):713-24. PubMed ID: 4705416
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.